Dr Reddys Laboratories (RDY) Return on Assets (2009 - 2026)
Dr Reddys Laboratories (RDY) posted quarterly Return on Assets of 0.0% for Q1 2026, little changed year-over-year from 0.0% in Q1 2025, and down 56.64% quarter-over-quarter from 0.0% in Q1 2025.
Dr Reddys Laboratories (RDY) Return on Assets (2009 - 2026) Analysis & Trends
Dr Reddys Laboratories' Return on Assets history runs 3 years deep, the most recent figure standing at 0.0% for Q1 2026.
- In Q1 2026, Return on Assets changed 0.0% year-over-year to 0.0%; the TTM figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), while the FY2026 annual figure was 0.0%, changed 0.0% from the prior year.
- Return on Assets for Q1 2026 stood at 0.0%, down from 0.0% in the prior quarter.
- The five-year high for Return on Assets was 0.0% in Q1 2025, with the low at 0.0% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 0.00% |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 0.00% |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 0.00% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 0.00% |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 0.00% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 0.00% |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 0.00% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 0.00% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 0.00% |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | 0.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.00% |
| Mar 31, 2025 | 0.00% |
| Dec 31, 2009 | 0.00% |
| Sep 30, 2009 | 0.00% |